Closure of Trading Window
Earkart Ltd operates in Medical Equipment & Supplies within the Healthcare sector.
160 historical price candles were omitted because the exchange source has not been verified.
Structured signal from quality, growth, valuation and momentum.
₹ crore, by fiscal year
% of revenue, by fiscal year
Comparable companies from the narrowest available industry classification.
Reported profit and loss, balance sheet, cash flow and growth history.
Annual operating, return, leverage and working-capital ratios.
Current futures and options contracts with compact option-chain pages.
Mutual-fund schemes that disclosed a holding in the company.
Annual reports, exchange filings, offer documents, ratings and earnings-call material.
Upcoming dates and the company’s corporate-action history.
Latest exchange announcements, filings and downloadable documents.
Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.
Standalone figures
| Ratio | Mar 2026 |
|---|---|
| Margins | |
| Gross margin % | 39.1% |
| EBITDA margin % | 15.5% |
| EBIT margin % | 14.2% |
| PAT margin % | 9.1% |
| Working capital | |
| Receivable days | 142 |
| Inventory days | 121 |
| Payable days | 20 |
| NWC days | 243 |
| Leverage | |
| Current ratio | 12.67 |
| Debt to EBITDA | 0 |
| Debt to equity | 0 |
| Interest coverage | 14.4 |
| Asset turnover | 0.78 |
| Return ratios | |
| Return on assets % | 7.1% |
| Return on capital employed % | 12.1% |
| Return on equity % | 7.7% |
Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.
Promoter holding up 0 percentage points since Sep 2025.
Current officeholders as filed with BSE. A person holding two offices is listed once per office.
Documents link to external sources (exchange filings, company investor pages).
No scheme among the 32 fund houses on record reported a position in Earkart Ltd. Portfolios are published monthly by each AMC; coverage is still partial.
Corporate actions, results dates and filings will appear here once ingested.
| Company | Mkt Cap | EV | Revenue | EBITDA | OPM | PAT | NPM | ROCE | ROE | WC Days |
|---|---|---|---|---|---|---|---|---|---|---|
| Molbio Diagnostics LimitedMOLBIOMOLBIO | ₹17,431 Cr | ₹17,844 Cr | ₹1,020 Cr | ₹262 Cr | 25.7% | ₹145 Cr | 13.6% | 23.7% | 16.2% | — |
| Poly Medicure LimitedPOLYMEDPOLYMED | ₹16,610 Cr | ₹16,952 Cr | ₹1,997 Cr | ₹461 Cr | 23.6% | ₹315 Cr | 17.1% | 14.5% | 11% | 294 |
| Fischer Medical Ventures LimitedFISCHERFISCHER | ₹2,190 Cr | ₹2,262 Cr | ₹367 Cr | ₹50 Cr | 14% | ₹30 Cr | 10.1% | 13.6% | 8.6% | 111 |
| Tarsons Products LimitedTARSONSTARSONS | ₹1,752 Cr | ₹2,135 Cr | ₹441 Cr | ₹119 Cr | 27.9% | ₹11 Cr | 3.4% | 5% | 2.3% | 361 |
| Laxmi Dental LimitedLAXMIDENTLLAXMIDENTL | ₹1,066 Cr | ₹1,066 Cr | ₹287 Cr | ₹46 Cr | 15.6% | ₹31 Cr | 10.4% | 14.7% | 12.8% | 109 |
| Hemant Surgical Industries LtdHSILHSIL | ₹885 Cr | — | ₹232 Cr | ₹23 Cr | 10% | ₹18 Cr | 7.9% | — | — | — |
| Fabtech Technologies LimitedFABTECHFABTECH | ₹632 Cr | ₹675 Cr | ₹418 Cr | ₹45 Cr | 8.5% | ₹49 Cr | 9.3% | 15.5% | 12.9% | 55 |
| Prevest Denpro LtdPREVESTPREVEST | ₹452 Cr | — | ₹72 Cr | ₹25 Cr | 34.4% | ₹20 Cr | 28.5% | — | — | — |
| Nureca LimitedNURECANURECA | ₹332 Cr | ₹333 Cr | ₹153 Cr | ₹4 Cr | 0.1% | ₹4 Cr | 1.4% | 3.3% | 1.1% | 186 |
| Earkart LtdEARKARTEARKART | ₹179 Cr | ₹179 Cr | ₹54 Cr | ₹8 Cr | 15.5% | ₹5 Cr | 9.1% | 12.1% | 7.7% | 243 |
| Choksi Asia LtdCHOKSICHOKSI | ₹117 Cr | ₹119 Cr | ₹11 Cr | ₹-2 Cr | 13.8% | ₹2 Cr | 10.8% | 18.9% | 13.5% | 142 |
| Shree Pacetronix LtdSHREEPACSHREEPAC | ₹68 Cr | ₹71 Cr | ₹8 Cr | ₹1 Cr | 23.5% | ₹0 Cr | 14% | 27.4% | 18.9% | 385 |
| ₹ Cr | Mar 2026 |
|---|---|
| Revenue | 54 |
| COGS | 33 |
| Gross profit | 21 |
| 13 | |
| 8 | |
| OPM % | 15.5% |
| Depreciation | 1 |
| Interest | 1 |
| 0 | |
| Profit before tax | 7 |
| Tax | 2 |
| Tax % | 32% |
| PAT | 5 |
| PAT margin % | 9.1% |
| EPS (₹) | 8 |
| EPS adjusted (₹) | 3.6 |
| Annual report | Annual report for Mar 2026 |
| ₹ Cr | Mar 2026 |
|---|---|
| Equity capital | 14 |
| Reserves | 51 |
| 0 | |
| 5 | |
| Total equity & liabilities | 69 |
| 6 | |
| CWIP | 0 |
| Investments | 0 |
| 63 | |
| Total assets | 69 |
| ₹ Cr | Mar 2026 |
|---|---|
| -13 | |
| -5 | |
| 39 | |
| Net cash flow | 21 |
| Free cash flow | -18 |
| CFO / Operating profit % | -150.4% |